Is PRLD or PRTA more undervalued in 2026?

CirclFi compares Prelude Therapeutics Incorporat (PRLD) and Prothena Corporation plc (PRTA) using 13 institutional-grade valuation models. PRLD has a Quality of Company score of 5.9/10 while PRTA scores 6.8/10.

Which is a better buy — PRLD or PRTA?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do PRLD and PRTA valuations compare?

PRLD at $3.93 and PRTA at $9.98 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

PRLD vs PRTA Valuation Comparison 2026 — Intrinsic Value Analysis

PRLD

Biotechnology

Prelude Therapeutics Incorporat

Quality

5.9

out of 10

Value Trap

SAFE

Price

$3.93

Last close

Models

9/13

Active

PRTA

Biotechnology

Prothena Corporation plc

Quality

6.8

out of 10

Value Trap

LOW

Price

$9.98

Last close

Models

11/13

Active

Model-by-Model Comparison

Model	Type	PRLD Fair Value	PRLD Upside	PRTA Fair Value	PRTA Upside
Bayesian DCF	Intrinsic	$1.12	-71.6%	$4.46	-55.3%
Earnings Power Value	Intrinsic	—	—	$6.84	-35.7%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$1.75	-55.5%	$8.92	-10.6%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for PRLD vs PRTA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

PRLD vs PRTA — Which Stock Is More Undervalued?

PRTA scores higher with a 6.8/10 quality rating vs PRLD's 5.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Prelude Therapeutics Incorporat (PRLD) and Prothena Corporation plc (PRTA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

PRLD currently trades at $3.93 with a QOC of 5.9/10, while PRTA trades at $9.98 with a QOC of 6.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).